-
公开(公告)号：KR101349185B1
公开(公告)日：2014-01-16
申请号：KR1020060121960
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/166 , A61K31/045 , A61P3/04
Abstract: 본 발명은 지방대사 이상질환의 치료 및 예방용 약학 조성물에 관한 것으로, 화학식 1의 화합물을 유효성분으로 포함하는 본 발명의 약학 조성물은 인간 간세포에서 생체내 에너지 대사에 중요한 역할을 하는 아이소싸이트레이트 탈수소효소 3α (IDH3α) 프로모터와 카르니틴 팔미토일 트랜스퍼레이즈 1A (CPT1A) 프로모터의 활성을 증가시켜, 혈당 및 중성지방의 감소 및 결과적으로 체중의 감소를 가져오므로, 비만, 고지혈증, 당뇨병 등의 지방대사 이상질환의 예방 및 치료에 유용하게 사용될 수 있다.
-
公开(公告)号：KR1020080051239A
公开(公告)日：2008-06-11
申请号：KR1020060121960
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/166 , A61K31/045 , A61P3/04
Abstract: A pharmaceutical composition comprising compounds capable of increasing expressions of isocitrate dehydrogenase 3alpha(IDH3alpha) and carnitine palmitoyl transferase 1A(CPT1A) by increasing activity of their promoters is provided to reduce synthesis of fatty acid and promote oxidation of fatty acid, so that the composition is useful for treating and preventing lipid metabolism-related diseases. A pharmaceutical composition for treating and preventing lipid metabolism-related diseases comprises compounds represented by the formula(1) in which R1 is adamantly group or phenyl group substituted by H, OH or C1-C5 alkyl, and R2 is CONH or NHCO, and further comprises pharmaceutically acceptable carriers, excipients or diluents selected from lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, crystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
Abstract translation: 提供了包含通过提高其启动子的活性而能够增加异柠檬酸脱氢酶3α（IDH3α）和肉碱棕榈酰转移酶1A（CPT1A）的表达的化合物的药物组合物，用于减少脂肪酸的合成并促进脂肪酸的氧化，使得组合物 用于治疗和预防脂质代谢相关疾病。 用于治疗和预防脂质代谢相关疾病的药物组合物包括由式（1）表示的化合物，其中R1是金刚烷基或被H，OH或C1-C5烷基取代的苯基，R2是CONH或NHCO， 包括药学上可接受的载体，赋形剂或稀释剂，其选自乳糖，葡萄糖，蔗糖，山梨糖醇，甘露糖醇，木糖醇，赤藓糖醇，麦芽糖醇，淀粉，阿拉伯胶，藻酸盐，明胶，磷酸钙，硅酸钙，纤维素，甲基纤维素，结晶纤维素，聚乙烯吡咯烷酮 ，水，羟基苯甲酸甲酯，羟基苯甲酸丙酯，滑石，硬脂酸镁和矿物油。
-
Patent Agency Ranking
公开(公告)号：KR1020070070300A
公开(公告)日：2007-07-04
申请号：KR1020050069505
申请日：2005-07-29
Applicant: (주)아모레퍼시픽
CPC classification number: C12N15/113 , A61K8/606 , A61K31/7105 , A61Q19/02 , C12N2310/141
Abstract: A method for inhibiting melanosome migration by using prohibitin siRNA(small interference RNA) is provided to inhibit expression of prohibitin in a melanin synthesis cell and uniformed distribution of melanosome in the melanin synthesis cell, so that the skin is whitened. The melanosome migration to the end of melanin synthesis cell is inhibited by administering prohibitin siRNA into the melanin synthesis cell, melan-a, thereby inhibiting binding of prohibitin to melanophilin as a melanosome vehicle and uniformed distribution of melanosome in the melanin synthesis cell.
Abstract translation: 提供了通过使用prohibitin siRNA（小干扰RNA）抑制黑素体迁移的方法，以抑制黑色素合成细胞中的禁忌蛋白的表达和黑色素合成细胞中黑素体的均匀分布，从而使皮肤变白。 黑色素细胞迁移到黑色素合成细胞末端受到抑制黑色素合成细胞，黑色素a的抑制蛋白siRNA，从而抑制黑素素作为黑素体载体和黑素体合成细胞中黑素体分布均匀的结合。
-
公开(公告)号：KR101141907B1
公开(公告)日：2012-05-03
申请号：KR1020050069505
申请日：2005-07-29
Applicant: (주)아모레퍼시픽
Abstract: A method for inhibiting melanosome migration by using prohibitin siRNA(small interference RNA) is provided to inhibit expression of prohibitin in a melanin synthesis cell and uniformed distribution of melanosome in the melanin synthesis cell, so that the skin is whitened. The melanosome migration to the end of melanin synthesis cell is inhibited by administering prohibitin siRNA into the melanin synthesis cell, melan-a, thereby inhibiting binding of prohibitin to melanophilin as a melanosome vehicle and uniformed distribution of melanosome in the melanin synthesis cell.
-
公开(公告)号：KR1020080051235A
公开(公告)日：2008-06-11
申请号：KR1020060121955
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/12 , A61K31/05 , A61K31/136 , A61P3/04
Abstract: A pharmaceutical composition for treating and preventing lipid metabolism-related diseases is provided to increase activity of isocitrate dehydrogenase 3alpha(IDH3alpha) promoter and carnitine palmitoyl transferase 1A(CPT1A) promoter, so that blood sugar and neutral fat are reduced. A pharmaceutical composition for treating and preventing lipid metabolism-related diseases comprises compounds represented by the formula(1), wherein R1 is H or C1-C5 alkyl, R2 is H or OH and n is an integer from 1 to 3, and is formulated as tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, sterile injection solution or sterile powder, wherein the daily dosage of the compounds is 0.1-100 mg/kg. Further, the lipid metabolism-related diseases are obesity, hyperlipemia and diabetes.
Abstract translation: 提供了用于治疗和预防脂质代谢相关疾病的药物组合物，以增加异柠檬酸脱氢酶3α（IDH3alpha）启动子和肉碱棕榈酰转移酶1A（CPT1A）启动子的活性，从而降低血糖和中性脂肪。 用于治疗和预防脂质代谢相关疾病的药物组合物包括由式（1）表示的化合物，其中R 1为H或C 1 -C 5烷基，R 2为H或OH，n为1至3的整数， 作为片剂，丸剂，粉末，香囊，酏剂，悬浮液，乳剂，溶液，糖浆，气溶胶，软或硬明胶胶囊，无菌注射溶液或无菌粉末，其中化合物的日剂量为0.1-100mg / kg。 此外，脂质代谢相关疾病是肥胖，高脂血症和糖尿病。
-
公开(公告)号：KR101349187B1
公开(公告)日：2014-01-10
申请号：KR1020060121955
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/12 , A61K31/05 , A61K31/136 , A61P3/04
Abstract: 본 발명은 지방대사 이상질환의 치료 및 예방용 약학 조성물에 관한 것으로, 화학식 1의 화합물을 유효성분으로 포함하는 본 발명의 약학 조성물은 인간 간세포에서 생체내 에너지 대사에 중요한 역할을 하는 아이소싸이트레이트 탈수소효소 3α (IDH3α) 프로모터와 카르니틴 팔미토일 트랜스퍼레이즈 1A (CPT1A) 프로모터의 활성을 증가시켜, 혈당 및 중성지방의 감소 및 결과적으로 체중의 감소를 가져오므로, 비만, 고지혈증, 당뇨병 등의 지방대사 이상질환의 예방 및 치료에 유용하게 사용될 수 있다.
-
公开(公告)号：KR100774437B1
公开(公告)日：2007-11-08
申请号：KR1020060113662
申请日：2006-11-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/343 , A61K8/49 , A61Q19/02
CPC classification number: A61K8/4973 , A61K31/343 , A61Q19/02
Abstract: A skin external composition for skin-whitening containing manassantin B is provided to inhibit mobility of melanin by inhibiting binding of melanophilin as a carrier of melanosome in a melanocyte with myosin 5a, thereby forming melanosome aggregation and whitening the skin. A skin external composition for skin-whitening contains 0.001-10% of manassantin B which is extracted from Saururus chinensis Baill by extracting Saururus chinensis Baill with water or organic solvent selected from ethanol, methanol, butanol, ether, ethylacetate, chloroform and methylene chloride, filtering the extract, concentrating the filtered solution under reduced pressure, extracting the concentrate with methylene chloride and concentrating the extract under reduced pressure, and is formulated as solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation or spray.
Abstract translation: 提供含有马桑丁汀B的皮肤外用组合物，用于通过抑制作为黑素细胞的黑素体的载体的黑色素细胞与肌球蛋白5a的结合来抑制黑色素的迁移，从而形成黑素体聚集并使皮肤变白。 用于皮肤美白的皮肤外用组合物含有0.001-10％的苦参碱B，其通过用水或选自乙醇，甲醇，丁醇，乙醚，乙酸乙酯，氯仿和二氯甲烷的有机溶剂萃取中华白菜， 过滤浓缩滤液，减压浓缩萃取液，减压浓缩，配制成溶液，悬浮液，乳液，糊剂，凝胶，乳液，乳液，粉末，皂，表面活性剂， 含有清洁，油，粉底，乳液粉底，蜡基或喷雾剂。
-
-
-
-
-
-
Search Results
7
records
(took 0.033 seconds)
